The Brazilian private pharmaceutical market after the first ten years of the generics law
Objectives To describe changes in the private market for selected originators, branded generics (‘similares’), and generic products during the 10 years following passage of the Brazilian Generics Law. Methods We analyzed longitudinal data collected by IQVIA® on quarterly sales by wholesalers to reta...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-12-01
|
| Series: | Journal of Pharmaceutical Policy and Practice |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1186/s40545-019-0179-9 |
| _version_ | 1827593268749139968 |
|---|---|
| author | Andréa Dâmaso Bertoldi Anita K. Wagner Isabel Cristina Martins Emmerick Luisa Arueira Chaves Peter Stephens Dennis Ross-Degnan |
| author_facet | Andréa Dâmaso Bertoldi Anita K. Wagner Isabel Cristina Martins Emmerick Luisa Arueira Chaves Peter Stephens Dennis Ross-Degnan |
| author_sort | Andréa Dâmaso Bertoldi |
| collection | DOAJ |
| description | Objectives To describe changes in the private market for selected originators, branded generics (‘similares’), and generic products during the 10 years following passage of the Brazilian Generics Law. Methods We analyzed longitudinal data collected by IQVIA® on quarterly sales by wholesalers to retail pharmacies in Brazil from 1998 through 2010, grouped by originators, branded generics, and generic products in three therapeutic classes (antibiotics, antidiabetics, and antihypertensives). Outcomes included market share (proportion of the total private market volume), sales volume per capita, prices and number of manufacturers by group. Results In the private market share, generics became dominant in each therapeutic class but the speed of uptake varied. Originators consistently lost most market share while branded generics varied over time. By the end of the study period, generics were the most sold product type in all classes, followed by branded generics. The number of generic manufacturers increased in all classes, while branded generics increased just after the policy but then decreased slowly through the end of 2010. For approximately 50% of the antibiotics analyzed, branded generics and generics had lower prices than originators. For antidiabetics, branded generic and generic prices were quite similar during the period analyzed. Price trends for the various subclasses of antihypertensive exhibited very different patterns over time. Conclusion Sales of branded generics and originators decreased substantially in the three therapeutic classes analysed following the introduction of the generics policy in Brazil, but the time to market dominance of generics varied by class. |
| first_indexed | 2024-03-09T02:07:53Z |
| format | Article |
| id | doaj.art-b20e9f0d7311470cb31cb11348f21399 |
| institution | Directory Open Access Journal |
| issn | 2052-3211 |
| language | English |
| last_indexed | 2024-03-09T02:07:53Z |
| publishDate | 2019-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Pharmaceutical Policy and Practice |
| spelling | doaj.art-b20e9f0d7311470cb31cb11348f213992023-12-07T15:28:02ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112019-12-0112110.1186/s40545-019-0179-912315107The Brazilian private pharmaceutical market after the first ten years of the generics lawAndréa Dâmaso Bertoldi0Anita K. Wagner1Isabel Cristina Martins Emmerick2Luisa Arueira Chaves3Peter Stephens4Dennis Ross-Degnan5Postgraduate Program in Epidemiology,Department of Population Medicine,Department of Surgery, Division of Thoracic Surgery,Pharmacy School,IQVIA,Department of Population Medicine,Objectives To describe changes in the private market for selected originators, branded generics (‘similares’), and generic products during the 10 years following passage of the Brazilian Generics Law. Methods We analyzed longitudinal data collected by IQVIA® on quarterly sales by wholesalers to retail pharmacies in Brazil from 1998 through 2010, grouped by originators, branded generics, and generic products in three therapeutic classes (antibiotics, antidiabetics, and antihypertensives). Outcomes included market share (proportion of the total private market volume), sales volume per capita, prices and number of manufacturers by group. Results In the private market share, generics became dominant in each therapeutic class but the speed of uptake varied. Originators consistently lost most market share while branded generics varied over time. By the end of the study period, generics were the most sold product type in all classes, followed by branded generics. The number of generic manufacturers increased in all classes, while branded generics increased just after the policy but then decreased slowly through the end of 2010. For approximately 50% of the antibiotics analyzed, branded generics and generics had lower prices than originators. For antidiabetics, branded generic and generic prices were quite similar during the period analyzed. Price trends for the various subclasses of antihypertensive exhibited very different patterns over time. Conclusion Sales of branded generics and originators decreased substantially in the three therapeutic classes analysed following the introduction of the generics policy in Brazil, but the time to market dominance of generics varied by class.http://dx.doi.org/10.1186/s40545-019-0179-9generic medicinespharmaceutical policymarket sharepricesbrazil |
| spellingShingle | Andréa Dâmaso Bertoldi Anita K. Wagner Isabel Cristina Martins Emmerick Luisa Arueira Chaves Peter Stephens Dennis Ross-Degnan The Brazilian private pharmaceutical market after the first ten years of the generics law Journal of Pharmaceutical Policy and Practice generic medicines pharmaceutical policy market share prices brazil |
| title | The Brazilian private pharmaceutical market after the first ten years of the generics law |
| title_full | The Brazilian private pharmaceutical market after the first ten years of the generics law |
| title_fullStr | The Brazilian private pharmaceutical market after the first ten years of the generics law |
| title_full_unstemmed | The Brazilian private pharmaceutical market after the first ten years of the generics law |
| title_short | The Brazilian private pharmaceutical market after the first ten years of the generics law |
| title_sort | brazilian private pharmaceutical market after the first ten years of the generics law |
| topic | generic medicines pharmaceutical policy market share prices brazil |
| url | http://dx.doi.org/10.1186/s40545-019-0179-9 |
| work_keys_str_mv | AT andreadamasobertoldi thebrazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT anitakwagner thebrazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT isabelcristinamartinsemmerick thebrazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT luisaarueirachaves thebrazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT peterstephens thebrazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT dennisrossdegnan thebrazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT andreadamasobertoldi brazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT anitakwagner brazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT isabelcristinamartinsemmerick brazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT luisaarueirachaves brazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT peterstephens brazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw AT dennisrossdegnan brazilianprivatepharmaceuticalmarketafterthefirsttenyearsofthegenericslaw |